RxDoctor Payments Data

Lorah Moye

Family · Statesboro, GANPI 1710346374

Payments from drug & device makers

$8,304in general payments, 2019–2025

Across 460 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Amgen$620
  • AstraZeneca$376
  • Lilly USA, LLC$324
  • Pfizer$307
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$8,304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,304 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$41,262
Medicare patients
120
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$85,122
OzempicSemaglutide47$66,530
JardianceEmpagliflozin21$17,499
LinzessLinaclotide13$14,133
EliquisApixaban12$9,256
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,820
ArexvyRsvpref3 Antigen/As01e/Pf27$8,566
JanumetSitagliptin Phos/Metformin Hcl11$6,317
SymbicortBudesonide/Formoterol Fumarate16$5,629
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,319
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,045
Tramadol Hcl56$1,900
Levothyroxine Sodium118$1,734
Sumatriptan Succinate24$1,693
SynthroidLevothyroxine Sodium28$1,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$324$85,12278 claims
Novo NordiskOzempic$1,110$66,53047 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$285$21,70560 claims
Boehringer IngelheimJardiance$173$17,49921 claims
AbbVieLinzess, Synthroid$1,186$15,71141 claims
PfizerEliquis$307$9,25612 claims
MerckJanumet$168$6,31711 claims
AstraZenecaSymbicort$376$5,62916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →